{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:04:24Z","timestamp":1793394264013,"version":"4.5.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Perosphere Pharmaceuticals Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\u2003<\/jats:title>\n                    <jats:p>Ciraparantag is a reversal agent for anticoagulants including direct oral anticoagulants. The aim was to evaluate the efficacy and safety of ciraparantag to reverse anticoagulation induced by apixaban or rivaroxaban in healthy elderly adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results\u2003<\/jats:title>\n                    <jats:p>Two randomized, placebo-controlled, dose-ranging trials conducted in healthy subjects aged 50\u201375 years. Subjects received apixaban (Study 1) 10 mg orally twice daily for 3.5 days or rivaroxaban (Study 2) 20 mg orally once daily for 3 days. At steady-state anticoagulation subjects were randomized 3:1 to a single intravenous dose of ciraparantag (Study 1: 30, 60, or 120 mg; Study 2: 30, 60, 120, or 180 mg) or placebo. Efficacy was based on correction of the whole blood clotting time (WBCT) at multiple timepoints over 24 h. Subjects and technicians performing WBCT testing were blinded to treatment. Complete reversal of WBCT within 1 h post-dose and sustained through 5 h (apixaban) or 6 h (rivaroxaban) was dose related and observed with apixaban in 67%, 100%, 100%, and 17% of subjects receiving ciraparantag 30 mg, 60 mg, 120 mg, or placebo, respectively; and with rivaroxaban in 58%, 75%, 67%, 100%, and 13% of subjects receiving ciraparantag 30 mg, 60 mg, 120 mg, 180 mg, or placebo, respectively. Adverse events related to ciraparantag were mild, transient hot flashes or flushing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\u2003<\/jats:title>\n                    <jats:p>Ciraparantag provides a dose-related reversal of anticoagulation induced by steady-state dosing of apixaban or rivaroxaban. Sustained reversal was achieved with 60 mg ciraparantag for apixaban and 180 mg ciraparantag for rivaroxaban. All doses of ciraparantag were well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab637","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T07:44:26Z","timestamp":1631087066000},"page":"985-992","source":"Crossref","is-referenced-by-count":48,"title":["Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1237-9797","authenticated-orcid":false,"given":"Jack","family":"Ansell","sequence":"first","affiliation":[{"name":"Hofstra Northwell School of Medicine , 500 Hofstra Blvd., Hempstead, NY 11549, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8805-9917","authenticated-orcid":false,"given":"Sasha","family":"Bakhru","sequence":"additional","affiliation":[{"name":"Perosphere Technologies Inc. , 108 Mill Plain Rd., Danbury, CT 06811, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan E","family":"Laulicht","sequence":"additional","affiliation":[{"name":"Landsdowne Laboratories Inc. , 1073 N. Benson Rd., Fairfield, CT 06824, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Tracey","sequence":"additional","affiliation":[{"name":"Frontage Clinical Services, Inc. , 200 Meadowlands Pkwy, Secaucus, NJ 07094, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Villano","sequence":"additional","affiliation":[{"name":"AMAG Pharmaceuticals, Inc. , 1100 Winter St., Waltham, MA 02450, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Freedman","sequence":"additional","affiliation":[{"name":"AMAG Pharmaceuticals, Inc. , 1100 Winter St., Waltham, MA 02450, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"2022102614545996200_ehab637-B1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102614545996200_ehab637-B2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"2022102614545996200_ehab637-B3","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"2022102614545996200_ehab637-B4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/rth2.12222","article-title":"Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017","volume":"3","author":"Lutsey","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2022102614545996200_ehab637-B5","first-page":"1710","article-title":"Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management\u2014a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis","volume":"38","author":"Niessner","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102614545996200_ehab637-B6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102614545996200_ehab637-B7","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102614545996200_ehab637-B8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12028-019-00866-6","article-title":"Key points to consider when evaluating Andexxa for formulary addition","volume":"33","author":"Peled","year":"2020","journal-title":"Neurocrit Care"},{"key":"2022102614545996200_ehab637-B9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.2020007116","article-title":"Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants","volume":"137","author":"Ansell","year":"2021","journal-title":"Blood"},{"key":"2022102614545996200_ehab637-B10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb Haemost"},{"key":"2022102614545996200_ehab637-B11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2016.07.008","article-title":"Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin","volume":"146","author":"Ansell","year":"2016","journal-title":"Thromb Res"},{"key":"2022102614545996200_ehab637-B12","first-page":"1","article-title":"Reversal of factor Xa inhibitors by andexanet alfa may increase thrombogenesis compared to pretreatment values","volume":"25","author":"Siddiqui","year":"2019","journal-title":"Clin Appl Thrombo Haemost"},{"key":"2022102614545996200_ehab637-B13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/10\/985\/46645769\/ehab637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/10\/985\/46645769\/ehab637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T11:37:27Z","timestamp":1666784247000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/10\/985\/6371852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,9,17]]},"published-print":{"date-parts":[[2022,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab637","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,7]]},"published":{"date-parts":[[2021,9,17]]}}}